Elfström K Miriam, Dillner Joakim, Arnheim-Dahlström Lisen
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, 171 77 Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, 171 77 Stockholm, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Alfred Nobels Allé 8, 141 83 Stockholm, Sweden.
Vaccine. 2015 Mar 30;33(14):1673-81. doi: 10.1016/j.vaccine.2015.02.028. Epub 2015 Feb 23.
HPV vaccination is underway in most European countries, but there are limited efforts toward optimization and standardization of organization, monitoring and evaluation. Our Europe-wide survey sought to identify how programs are currently organized, the costs associated with the organizing and ensuring quality of the program and how quality and effectiveness measurements are carried out.
A comprehensive questionnaire was developed through systematic literature review and the European guidelines for quality assurance in cervical screening. The survey was piloted in a sub-set of countries and then sent to program organizers, Ministries of Health, and key experts in 34 EU and EFTA countries (including countries within the UK). Detailed information on program organization and target population, monitoring and evaluation (including indicators used for evaluating the impact of vaccination), and associated costs were collected. In addition, documentation of program guidelines, protocols, and publications were requested.
Of the 34 countries contacted, 27 responded. The majority of countries had some level of vaccination activity, with approximately half of the countries reporting an organized vaccination program. Centralized vaccine registries were in place in the majority of countries with an organized program, allowing for monitoring of key indicators at the national level. Costs of organization and monitoring were difficult to estimate and varied significantly, as some countries were able to use existing infrastructures while others had to create new systems, incurring greater costs.
The organization and quality of HPV vaccination programs differ across countries and, in some instances, even across regions within the same country. The monitoring being performed varies across programs with regard to level of detail but engagement in the survey from the participating countries demonstrates that there is strong interest in reflecting on and improving program performance. This survey could serve as a basis for strengthening surveillance of HPV vaccination programs.
大多数欧洲国家正在开展人乳头瘤病毒(HPV)疫苗接种工作,但在优化组织、监测和评估的标准化方面所做的努力有限。我们在全欧洲范围内进行的调查旨在确定目前项目的组织方式、组织和确保项目质量所涉及的成本,以及质量和效果的衡量方式。
通过系统的文献综述和欧洲宫颈癌筛查质量保证指南制定了一份综合问卷。该调查先在部分国家进行试点,然后发送给34个欧盟和欧洲自由贸易联盟国家(包括英国境内的国家)的项目组织者、卫生部和关键专家。收集了有关项目组织和目标人群、监测和评估(包括用于评估疫苗接种影响的指标)以及相关成本的详细信息。此外,还要求提供项目指南、方案和出版物的文件。
在联系的34个国家中,27个国家作出了回应。大多数国家都有一定程度的疫苗接种活动,约一半国家报告有组织的疫苗接种项目。大多数有组织项目的国家都设有中央疫苗登记处,以便在国家层面监测关键指标。组织和监测成本难以估算且差异很大,因为一些国家能够利用现有基础设施,而另一些国家则不得不创建新系统,成本更高。
HPV疫苗接种项目的组织和质量因国家而异,在某些情况下,甚至在同一个国家的不同地区也存在差异。不同项目的监测在详细程度上各不相同,但参与调查的国家的参与表明,人们对反思和改进项目绩效有着浓厚兴趣。这项调查可作为加强HPV疫苗接种项目监测的基础。